美国癌症学会国家肺癌圆桌会议战略规划：改善非小细胞肺癌全面生物标志物检测的途径

The American Cancer Society National Lung Cancer Roundtable strategic plan: Methods for improving turnaround time of comprehensive biomarker testing in non-small cell lung cancer

CANCER

影响因子:5.1

分区:医学1区 Top / 肿瘤学2区

发表日期:2024 Dec 15

作者: Sinchita Roy-Chowdhuri, Haresh Mani, Adam H Fox, Anne Tsao, Lynette M Sholl, Farhood Farjah, Bruce E Johnson, Raymond U Osarogiagbon, M Patricia Rivera, Gerard A Silvestri, Robert A Smith, Ignacio I Wistuba

DOI: 10.1002/cncr.34926

摘要

对非小细胞肺癌患者进行全面生物标志物检测对于选择合适的靶向治疗或免疫治疗至关重要。确保及时的检测订购、处理和报告是优化患者预后的关键。然而，各种因素可能阻碍或延迟患者获得基于全面生物标志物检测的治疗选择。这些因素包括检测的可及性、组织样本的充分性、周转时间以及医疗保险覆盖和账单实践。周转时间依赖于多种后勤和组织样本处理因素，包括机构政策、流程、资源、检测方法和不同实践中的检测算法。在本文中，作者识别了延长生物标志物检测周转时间的关键因素，提出了缩短方法，并提供了流程图以帮助医生和关键组织利益相关者提高检测效率。

Abstract

Comprehensive biomarker testing for patients with non-small cell lung cancer is critical for selecting appropriate targeted therapy or immunotherapy. Ensuring timely ordering, processing, and reporting is key to optimizing patient outcomes. However, various factors can prevent or delay patients from being offered the option of treatment selection based on comprehensive biomarker testing. These factors include problems with access to testing, tissue adequacy, turnaround time, and health insurance coverage and billing practices. Turnaround time depends on several logistical and tissue handling factors, which involve institutional policies, processes, resources, testing methodology, and testing algorithms that vary across different practices. In this article, the authors identify key factors that prolong biomarker testing turnaround time, propose strategies to reduce it, and present a process map to aid physicians and key organizational stakeholders in improving testing efficiency.